渐进性神经内分泌肿瘤患者中[177Lu]Lu-satoreotide tetraxetan的剂量学与药代动力学
该研究为[177Lu]Lu-satoreotide tetraxetan的I/II期试验的一部分,40例渐进性神经内分泌肿瘤患者接受中位累积活度13.0 GBq、计划三周期(中位每周期活度4.5 GBq)的治疗,每周期进行患者特异性剂量学监测。结果显示肾脏为主要清除途径,首次治疗周期后48小时内累积排泄57-66%,肿瘤中位吸收剂量系数为5.0 Gy/GBq,三周期后骨髓和肾脏中位累积吸收剂量分别为1.1和10.8 Gy。结论认为该药物剂量学特征良好,肿瘤摄取高且持久。
要点
- 40例渐进性神经内分泌肿瘤患者接受中位累积活度13.0 GBq、计划三周期、中位每周期4.5 GBq的治疗。
- 首次治疗周期后48小时内肾脏累积排泄57-66%,为主要的清除途径。
- 首次治疗周期肿瘤中位吸收剂量系数5.0 Gy/GBq,三周期后骨髓和肾脏中位累积吸收剂量分别为1.1和10.8 Gy。
核心结论
- [177Lu]Lu-satoreotide tetraxetan显示出良好的剂量学特征,肿瘤摄取高且持久,支持其可接受的安全性和有前景的疗效。
研究设计与样本
- 该研究为[177Lu]Lu-satoreotide tetraxetan的I/II期试验的一部分,纳入40例渐进性神经内分泌肿瘤患者,中位累积活度为13.0 GBq,计划三周期,中位每周期活度4.5 GBq,每周期采用患者特异性剂量学监测器官吸收剂量。
主要发现
- 所有评估器官中[177Lu]Lu-satoreotide tetraxetan的最大摄取出现在第一个成像时间点(注射后4小时),随后呈指数下降;首次治疗周期后48小时内肾脏累积排泄57-66%;首次治疗周期中位终末血液半衰期为127小时;首次治疗周期肿瘤中位吸收剂量系数为5.0 Gy/GBq,骨髓0.1 Gy/GBq,肾脏0.9 Gy/GBq,肝脏0.2 Gy/GBq,脾脏0.8 Gy/GBq;基于图像剂量学,三周期后骨髓和肾脏中位累积吸收剂量分别为1.1和10.8 Gy。
关键数值与推荐
- 累积吸收剂量限值设定为肾脏23.0 Gy、骨髓1.5 Gy;部分患者同时采用患者特异性剂量学和基于模型的剂量学计算吸收剂量系数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [177Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs). METHODS: This study was part of a phase I/II trial of [177Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three planned cycles (median activity/cycle: 4.5 GBq), in 40 patients with progressive NETs. Organ absorbed doses were monitored at each cycle using patient-specific dosimetry; the cumulative absorbed-dose limits were set at 23.0 Gy for the kidneys and 1.5 Gy for bone marrow. Absorbed dose coefficients (ADCs) were calculated using both patient-specific and model-based dosimetry for some patients. RESULTS: In all evaluated organs, maximum [177Lu]Lu-satoreotide tetraxetan uptake was observed at the first imaging timepoint (4 h after injection), followed by an exponential decrease. Kidneys were the main route of elimination, with a cumulative excretion of 57-66% within 48 h following the first treatment cycle. At the first treatment cycle, [177Lu]Lu-satoreotide tetraxetan showed a median terminal blood half-life of 127 h and median ADCs of [177Lu]Lu-satoreotide tetraxetan were 5.0 Gy/GBq in tumours, 0.1 Gy/GBq in the bone marrow, 0.9 Gy/GBq in kidneys, 0.2 Gy/GBq in the liver and 0.8 Gy/GBq in the spleen. Using image-based dosimetry, the bone marrow and kidneys received median cumulative absorbed doses of 1.1 and 10.8 Gy, respectively, after three cycles. CONCLUSION: [177Lu]Lu-satoreotide tetraxetan showed a favourable dosimetry profile, with high and prolonged tumour uptake, supporting its acceptable safety profile and promising efficacy. TRIAL REGISTRATION: NCT02592707. Registered October 30, 2015.
引用
- Schürrle SB, Eberlein U, Ansquer C, et al. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2024. PMID: 38528164. doi:10.1007/s00259-024-06682-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。